A Retrospective Study of Trifluridine/Tipiracil with Fruquintinib in Patients with Chemorefractory Metastatic Colorectal Cancer

Overview

Journal J Clin Med

Specialty General Medicine

Date 2024 Jan 11

PMID 38202064

Authors

Jiayun Zou

Yuanyuan Wang

Jiayu Xu

Jinna Li

Tianzhuo Wang

Ying Zhang

Yibo Bai

Affiliations

Soon will be listed here.

Abstract

Introduction: Trifluridine/tipiracil (TAS-102) and fruquintinib are novel antitumor agents for patients with refractory metastatic colorectal cancer (mCRC). We conducted a retrospective study to explore the clinical efficacy and drug toxicities of combination therapy with TAS-102 and fruquintinib in real-life clinical practice.

Methods: Between March 2021 and February 2023, patients at two different centers with mCRC who failed two or more lines of prior therapy and received TAS-102 in combination with fruquintinib were recruited.

Results: In total, 32 mCRC patients were included in the analysis. The objective response rate (ORR) and the disease control rate (DCR) were 9.4% and 75%. The median progression-free survival (PFS) and overall survival (OS) were 6.3 (95% CI: 5.3-7.3) and 13.5 (95% CI: 9.5-17.5) months, respectively. Patients without liver metastasis or peritoneal metastasis obtained better median PFS (7.1 m vs. 5.6 m, = 0.03 and 6.3 m vs. 3.4 m, = 0.04), and OS (15.2 m vs. 10.4 m, = 0.01 and 13.6 m vs. 7.1 m, = 0.03), respectively. Other clinicopathological features, including age, tumor site, KRAS status, dosage of fruquintinib, and treatment line, did not affect the clinical efficacy of TAS-102 combined with fruquintinib. The most common grade three-four toxicities were neutropenia (46.9%), anemia (21.9%), diarrhea (15.6%), nausea (12.5%), and hand-foot syndrome rash (12.5%).

Conclusions: Our results suggest that TAS-102 combined with fruquintinib has promising clinical efficacy and manageable safety for refractory mCRC patients in a real-world clinical setting. Further prospective trials are warranted to confirm our results.

Citing Articles

Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study.

Wang X, Bai Z, Deng W, Wang X Invest New Drugs. 2025; .

PMID: 39945972 DOI: 10.1007/s10637-025-01510-1.

References

Weng S, Yuan Y, Wang X, Chen G, Wang Y, Sheng W . Updates in version 2020 of CSCO guidelines for colorectal cancer from version 2019. Chin J Cancer Res. 2020; 32(3):403-407. PMC: 7369177. DOI: 10.21147/j.issn.1000-9604.2020.03.11. View

Li F, Lin Y, Li R, Shen X, Xiang M, Xiong G . Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches. Front Pharmacol. 2023; 14:1165666. PMC: 10622804. DOI: 10.3389/fphar.2023.1165666. View

Xu J, Kim T, Shen L, Sriuranpong V, Pan H, Xu R . Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Trifluridine/Tipiracil (TAS-102) Monotherapy in Asian Patients With Previously Treated Metastatic Colorectal Cancer: The TERRA Study. J Clin Oncol. 2017; 36(4):350-358. DOI: 10.1200/JCO.2017.74.3245. View

Pfeiffer P, Yilmaz M, Moller S, Zitnjak D, Krogh M, Petersen L . TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 2020; 21(3):412-420. DOI: 10.1016/S1470-2045(19)30827-7. View

Iorio J, Lastraioli E, Tofani L, Petroni G, Antonuzzo L, Messerini L . hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients. Transl Oncol. 2020; 13(3):100740. PMC: 7044526. DOI: 10.1016/j.tranon.2020.01.001. View

Guan X, Li H, Xiong X, Peng C, Wang N, Ma X . Cost-effectiveness analysis of fruquintinib versus regorafenib as the third-line therapy for metastatic colorectal cancer in China. J Med Econ. 2021; 24(1):339-344. DOI: 10.1080/13696998.2021.1888743. View

Nukatsuka M, Nakagawa F, Saito H, Sakata M, Uchida J, Takechi T . Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts. Anticancer Res. 2015; 35(3):1437-45. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Matsuoka K, Nakagawa F, Kobunai T, Takechi T . Trifluridine/tipiracil overcomes the resistance of human gastric 5-fluorouracil-refractory cells with high thymidylate synthase expression. Oncotarget. 2018; 9(17):13438-13450. PMC: 5862589. DOI: 10.18632/oncotarget.24412. View

10.

Elamin Y, Rafee S, Osman N, O Byrne K, Gately K . Thymidine Phosphorylase in Cancer; Enemy or Friend?. Cancer Microenviron. 2015; 9(1):33-43. PMC: 4842186. DOI: 10.1007/s12307-015-0173-y. View

11.

Sakamoto K, Yokogawa T, Ueno H, Oguchi K, Kazuno H, Ishida K . Crucial roles of thymidine kinase 1 and deoxyUTPase in incorporating the antineoplastic nucleosides trifluridine and 2'-deoxy-5-fluorouridine into DNA. Int J Oncol. 2015; 46(6):2327-34. PMC: 4441292. DOI: 10.3892/ijo.2015.2974. View

12.

Adam R, Wicherts D, de Haas R, Ciacio O, Levi F, Paule B . Patients with initially unresectable colorectal liver metastases: is there a possibility of cure?. J Clin Oncol. 2009; 27(11):1829-35. DOI: 10.1200/JCO.2008.19.9273. View

13.

Murakami Y, Kazuno H, Emura T, Tsujimoto H, Suzuki N, Fukushima M . Different mechanisms of acquired resistance to fluorinated pyrimidines in human colorectal cancer cells. Int J Oncol. 2000; 17(2):277-83. DOI: 10.3892/ijo.17.2.277. View

14.

Matsuoka K, Nakagawa F, Tanaka N, Okabe H, Matsuo K, Takechi T . Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells. Int J Mol Sci. 2018; 19(10). PMC: 6213129. DOI: 10.3390/ijms19102915. View

15.

Stewart C, Warner S, Ito K, Raoof M, Wu G, Kessler J . Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?. Curr Probl Surg. 2018; 55(9):330-379. PMC: 6422355. DOI: 10.1067/j.cpsurg.2018.08.004. View

16.

Franko J, Shi Q, Goldman C, Pockaj B, Nelson G, Goldberg R . Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2011; 30(3):263-7. PMC: 3269953. DOI: 10.1200/JCO.2011.37.1039. View

17.

Riedesser J, Ebert M, Betge J . Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol. 2022; 14:17588359211072703. PMC: 8882813. DOI: 10.1177/17588359211072703. View

18.

Qin S, Li J, Bai Y, Deng Y, Yang L, Xu R . Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib in the FRESCO trial. Future Oncol. 2021; 17(15):1923-1931. DOI: 10.2217/fon-2020-1215. View

19.

Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A . Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin. 2022; 72(4):372-401. DOI: 10.3322/caac.21728. View

20.

Liu G, Franssen E, Fitch M, Warner E . Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997; 15(1):110-5. DOI: 10.1200/JCO.1997.15.1.110. View